health and disease, which includes activation of platelets and ECs, as well as regulation of inflammation and coagulation. [2] [3] [4] [5] Moreover, microvesicles were reported as a predictor of future cardiovascular events in a population with stable CAD and high Framingham risk scores. 6, 7 Notably, plasma microvesicle levels are also associated with clinical outcomes in several cardiometabolic diseases, including coronary artery disease, chronic renal failure, diabetes mellitus, and obesity. [8] [9] [10] [11] [12] MiRs are noncoding small RNAs that regulate gene expression at the post-transcriptional level. 13 Multiple studies have demonstrated that the expression levels of circulating miRs both in tissue and plasma are altered in several cardiovascular pathologies. Because of their incorporation into extracellular vesicles, miRs show a high stability in fluids (eg, blood plasma) and are reliably detectable in the blood. 14 Therefore, circulating miRs have emerged as a novel class of biomarkers for patients with CAD. 15 Previously, we and others have proposed that the transfer of microvesicle-associated miRs may modulate the biological functions of the acceptor cell. 5, 16 Importantly, high expression levels of vasculoprotective miRs within microvesicles show atheroprotective effects in experimental murine models of vascular injury and atherosclerosis 5, 17, 18 and are associated with a reduced rate of major adverse cardiovascular events in patients with stable CAD. 19 However, it is still unknown whether vascular or myocardial miRs are selectively packaged into circulating microvesicles in response to atherosclerotic conditions. Because miR-containing microvesicles regulate vascular function and disease progression, a detailed exploration of miR expression in circulating microvesicles in patients with stable CAD, acute coronary syndrome (ACS), and angiographically excluded CAD would be of high interest to further understand the pathogenesis of CAD and develop novel therapeutic strategies.
Herein, evidence is provided that clinical and experimental atherosclerotic conditions can promote the packaging of functional miR-92a-3p into microvesicles, thus promoting angiogenic responses in the recipient cells.
Methods
An extended Materials and Methods is provided in the Online Data Supplement.
The data that support the findings of this study are available from the corresponding author on reasonable request
Results

Study Design
Between August 2012 and July 2013, 233 patients presenting with symptoms of stable CAD or ACS in our outpatient and emergency department were enrolled in the study. To identify alterations in miR expression in microvesicles between stable CAD and ACS patients, we first performed miR screening. Specifically, the miR profile in isolated circulating microvesicles from stable CAD (n=5) and ACS patients (n=5) was assessed using a Taqman miR array. To validate the miR array results, another 223 patients were screened for inclusion. Among those, 43 patients with malignant diseases (n=8), inflammatory diseases (n=15), severe hepatic or renal dysfunction (n=13), or declination of participation (n=7) were excluded from the study. Therefore, a total of 180 patients were prospectively included ( Figure 1 ). Patients were classified into 3 groups: angiographic exclusion of obstructive CAD (<50% stenosis of a major coronary artery, named as no CAD [NCAD], n=41), stable CAD (n=77), or ACS (n=62; Figure 1 ; Online Table I ).
Baseline Characteristics
There was no difference with respect to age among the 3 groups. Most of the patients (68.9%) enrolled were men, which was driven by higher numbers of male patients in the stable CAD and ACS group (P=0.001). Stable CAD and ACS patients were more likely to have diabetes mellitus (P=0.042), hyperlipoproteinemia (P=0.043), and a lower left ventricular ejection fraction (P=0.004) compared with NCAD patients. Stable CAD and ACS patients more frequently took angiotensin-converting enzyme inhibitors, β-blockers, statins, aspirin, and clopidogrel. With regard to the laboratory parameters, serum creatinine, glucose, HbA1c, glomerular filtration rate, triglyceride, LDL (low-density lipoprotein) cholesterol, C-reactive protein, and leukocyte levels were similar in the 3 groups. Stable CAD and ACS patients showed reduced overall cholesterol (P=0.003) and HDL (high-density lipoprotein) cholesterol (P=0.001) levels compared with NCAD patients. The number of circulating annexin V/CD31+microvesicles did not vary significantly among the 3 groups (Online Table I ).
miR Selection and Detection in Circulating Microvesicles
Circulating miRs are protected while in the bloodstream by being confined to microvesicles and regulate the progression of CAD. 20 In addition, they have been associated with a number of cardiovascular outcomes. 19 However, the expression profile of microvesicle-miRs in patients with or without CAD has not yet been systematically explored. Therefore, the miR profile in isolated circulating microvesicles from stable CAD (n=5) and ACS patients (n=5) was assessed using a Taqman miR array. Among the multiple miRs that are differentially expressed between stable CAD and ACS patients (Online Figure  I ), 9 miRs with known regulatory roles in the development and progression of atherosclerosis and CAD were selected for prospective quantification in our validation cohort of 180 patients with NCAD, stable CAD, or ACS: miR-21-5p, 21 miR-26a-5p, 22 miR-92a-3p, 23 miR-126-3p, 5 miR-139-5p, 24 miR-199a-5p, 25 and miR-222-3p, 26 miR-let-7d-5p, 27 miR-30b-5p. 28, 29 Analysis of the miR expression pattern in isolated microvesicles from NCAD, stable CAD, and ACS patients showed no difference with respect to miR-21-5p, miR-26a-5p, miR-126-3p, miR-139-5p, miR-199a-5p, miR-222-3p, miR-let-7d-5p, and miR-30b-5p. In contrast, miR-92a-3p was significantly increased in stable CAD and ACS patients compared with NCAD patients (*P<0.05; Figure 2 ). Based on these observations, we sought to further characterize the role of microvesicle-incorporated miR-92a-3p.
Comorbidities such as hypertension and diabetes mellitus or medication could potentially affect circulating microvesicle-bound miR levels. However, binary logistic regression demonstrated that higher or lower levels of miR-92a-3p were not associated with any comorbidities (Online Table  II ). Furthermore, miR-92a-3p levels were independent of any drug therapy (Online Table II ).
miR-92a-3p Expression in Microvesicles, Exosomes, and Vesicle-Free Plasma
Circulating miRs in plasma can be transported within extracellular vesicles (exosomes, microvesicles, and apoptotic bodies) or bound to proteins (HDL, Ago-2 [argonaute-2]). Both routes provide remarkable stability and resistance to degradation from endogenous RNase activity. Next, we aimed to explore the plasma components (exosomes, microvesicles, and vesicle-free plasma) in which miR-92a-3p is mainly expressed. Consequently, microvesicles, exosomes, and vesicle-free plasma were collected by a series of centrifugation steps, and miR-92a-3p levels were analyzed in the subcompartments of 10 patients with stable CAD. Electron microscopy confirmed the proper isolation of exosomes and microvesicles as would be expected for the protocol used ( Figure 3A) . miR-92a-3p was primarily detected in microvesicles or vesicle-free plasma ( Figure 3B ).
Because circulating microvesicles are composed of different subspecies of membrane particles released from endothelial and blood cells, we sorted endothelial-, platelet-, and other cellderived microvesicles by using flow cytometry to explore the Figure 1 . Study flow. Pictured is the study protocol. We first performed microRNA (miR) screening. MiR profiles from isolated circulating microvesicles (MVs) from stable coronary artery disease (CAD; n=5) and acute coronary syndrome (ACS) patients (n=5) were assessed using a Taqman miR array. To validate the miR array results, a total of 180 patients with angiographically excluded CAD (n=41), stable CAD (n=77), and ACS (n=62) were prospectively included in the study. Circulating MVs were isolated from the plasma of patients using ultracentrifugation. MiRs derived from the isolated MVs were analyzed by real-time polymerase chain reaction (PCR). February 15, 2019 cellular origins of microvesicle-bound miR-92a-3p as described previously. 19, 22 Overall, miR-92a-3p showed the highest expression in CD31
− endothelial cell-derived microvesicles (EMVs), compared with CD31
+ platelet-derived microvesicles and CD31
− microvesicles (other cell-derived microvesicles; Figure 3C ). Similarly, in vitro, miR-92a-3p also showed the highest expression in EMVs, compared with platelet-derived microvesicles and monocyte-derived microvesicles ( Figure 3D ). These results suggest that miR-92a-3p is selectively packaged into EMVs in patients and in vitro.
oxLDL Stimulation in Vitro Increases EMVIncorporated miR-92a-3p Expression by Activating STAT3 in Donor ECs
Because microvesicle-incorporated miR-92a-3p was significantly increased in CAD patients and endothelial cellderived microvesicles were shown to be the major source of miR-92a-3p-containing microvesicles, we next explored the effect of known atherosclerotic conditions in vitro on miR expression in ECs and EMVs. As an independent risk factor for atherosclerosis, several lines of evidence indicate that LDL, and in particular its oxLDL (oxidized LDL), play a key role in endothelial dysfunction and atherogenesis. 30, 31 To explore whether oxLDL might affect miR levels in ECs and EMVs, ECs were incubated with oxLDL or native LDL for 24 hours, and EMVs were subsequently isolated. Real-time polymerase chain reaction (PCR) analysis of the 9 selected miRs revealed that mainly miR-92a-3p but also miR-222-3p and miR-26a-5p were selectively sorted into EMVs after oxLDL, compared with native LDL, stimulation ( Figure 4A ). To further investigate the link between oxLDL and miR-92a-3p, we quantified miR-92a-3p expression in ECs and EMVs after stimulation with native LDL or increasing oxLDL concentrations. OxLDL stimulation significantly increased miR-92a-3p expression both in EMVs and ECs in a dose-dependent manner ( Figure 4B and 4C).
Next, we explored whether oxLDL-induced miR-92a-3p upregulation is oxLDL specific or whether miR-92a-3p might be also induced by another atherosclerotic stimulus. IL-6 (interleukin-6) is one major player in the inflammatory cascade promoting atherosclerosis. Therefore, ECs were treated with IL-6 using a widely used cellular model to study inflammatoryassociated endothelial injury. [32] [33] [34] [35] Interestingly, IL-6 stimulation induced miR-92a-3p expression within ECs and EMVs (Online Figure IIA and IIB). Predominantly miR-92a-3p, but also miRlet-7d-5p, was sorted from cells into EMVs (Online Figure IIC) .
In summary, our findings indicate that 2 independent atherosclerotic stimuli (oxLDL and IL-6) induce cellular miR-92a-3p expression and increase miR-92a-3p expression within EMVs.
STAT3 (signal transducer and activator of transcription 3) is a transcription factor that controls a battery of genes involved in the regulation of a variety of biological processes. Previous studies identified a highly conserved STAT3-binding site in the promoter of the EFCAB12 gene, which encodes the entire miR-17-92 cluster.
14 Immunoblot experiments revealed that oxLDL enhanced STAT3 phosphorylation ( Figure 4D ). To examine the direct effect of STAT3 activation on miR-92a-3p expression in ECs and EMVs, we selectively blocked STAT3 activity using a STAT3 inhibitor (Stattic), and ECs were transfected with siRNA (small interfering RNA) against STAT3 or a scrambled siRNA control. Efficient STAT3 downregulation in target cells by using interfering RNA was confirmed by real-time PCR (Online Figure IIIA) . MiR-92a-3p expression analysis revealed that STAT3 inhibition significantly reduced miR-92a-3p expression in ECs and EMVs in a dose-dependent manner (Figure 4E 
miR-92a-3p in EMVs Regulates Target Cell Function
Increasing evidence suggests that microvesicles are the major transport vehicles for miRs and that the functions of microvesicles can be affected by the miRs contained within them. 16, 36, 37 To study the biological function of miR-92a-3p that is incorporated into EMVs, we investigated first and exosomes were isolated using 20 000g and 100 000g centrifugation. Characterization of MVs, exosomes, and the final supernatant was performed using electron microscopy. Magnification is ×46 000. B, MiR-92a-3p was quantified in MVs, exosomes (Ex), and vesicle-free supernatant (Sup) by realtime polymerase chain reaction (PCR; *P<0.05, n=6, by 1-way ANOVA with Bonferroni correction for multiple comparisons test). Cel-miR-39 was used for normalization. C, Endothelial cell-derived (CD31+/CD42b−), platelet-derived (CD31+/CD42b+), and other cell-derived (CD31−/CD42b−) MVs were collected from 10 plasma samples of patients with coronary artery disease (CAD), and miR-92a-3p expression was analyzed in each subgroup of MVs by real-time PCR (*P<0.05, n=10, by 1-way ANOVA with Bonferroni correction for multiple comparisons test). Cel-miR-39 was used for normalization. D, Endothelial cellderived MV (EMVs), platelet-derived MV (PMVs), and monocyte-derived MV (MMVs) were isolated from the corresponding cells, and miR-92a-3p expression was analyzed in each subgroup of MVs by real-time PCR (*P<0.05, **P<0.01, n=3-5, by 1-way ANOVA with Bonferroni correction for multiple comparisons test). RNU6B RNA was used as an endogenous control for normalization. February 15, 2019 whether microvesicles containing miR-92a-3p can be internalized by recipient ECs. To visualize the transport of miR-92a-3p using microvesicles from ECs into recipient cells, we transfected donor ECs with Cy3-labeled miR92a-3p (Cy3-miR-92a-3p) and isolated Cy3-miR-92a-3p containing EMVs from the donor ECs. Subsequently, EMVs were labeled with PKH67 (a general membrane dye). After incubation with labeled EMVs, colocalization of Cy3-miR-92a-3p (red) and PKH67 (green) was observed in most recipient ECs by using fluorescent microscopy ( Figure 5A ). Furthermore, copy number assays using real-time PCR showed that EMV-mediated transfer of miR92a-3p can significantly increase its expression in recipient cells ( Figure 5B ). To confirm the effective transfer of miR92a-3p via EMVs, we performed an additional knockdown experiment by silencing miR-92a-3p in ECs. Copy number assays showed that lower levels of miR-92a-3p in ECs after knockdown are restored after EMV treatment, returning almost to baseline levels compared with the control group (Online Figure IV) .
Next, we explored the biological function of EMVincorporated miR-92a-3p. Because miR-92a-3p has been shown to be a major regulator of angiogenesis, 38 we investigated whether the miR-92a-3p found in EMVs can functionally regulate target EC migration, proliferation, and tube formation. Therefore, a miR-92a-3p inhibitor was used to inhibit miR-92a-3p expression in ECs and EC-derived EMVs to generate EMV miR-92a-downregulated and the corresponding control group (EMV mock-transfected ). Efficient miR-92a-3p downregulation in EMV parent cells and EMVs by using an inhibitor was confirmed by real-time PCR, whereas expression of other ECderived miRs was neither affected in EMV donor cells nor in EMVs (Online Figures V and VI) . Copy number experiments revealed that downregulation of miR-92a-3p in EMVs resulted in a reduced transfer of miR-92a-3p to recipient ECs (Online Figure VII . Oxidized low-density lipoprotein (OxLDL) increases microRNA (miR-92a-3p) expression in ECs and EMVs. A, MiR-92a-3p, miR-21-5p, miR-26a-5p, miR-126-3p, miR-139-5p, miR-199a-5p, miR-222-3p, miR-let-7d-5p, and miR-30b-5p were analyzed in oxLDL endothelial cell-derived microvesicle (EMVs) by using real-time PCR (*P<0.05, n=3, by Student t test). Native LDL (low-density lipoprotein) EMVs served as the control group. B and C, MiR-92a-3p was analyzed in endothelial cells (ECs) and EMVs after stimulation with native LDL or different oxLDL concentrations by using real-time PCR (*P<0.05, **P<0.01, ***P<0.001, n=5, by 1-way ANOVA with Bonferroni correction for multiple comparisons test). D, STAT3 (signal transducer and activator of transcription 3) and STAT3-Y705 (phosphorylated at tyrosine 705) protein levels were analyzed by Western blot in ECs that were treated with oxLDL or native LDL (control). β-Actin was used as the loading control (*P<0.05, n=3, by Student t test). E and F, MiR-92a-3p was measured in ECs and EMVs after incubation with different concentrations of a STAT3 inhibitor by real-time PCR (**P<0.01, ***P<0.001, n=5-6, by 1-way ANOVA with Bonferroni correction for multiple comparisons test). RNU6B RNA was used as an endogenous control in real-time PCR.
promoting angiogenic processes (Figure 6A through 6F; Online Figure VIII) .
Studies suggested that microvesicles play key roles in the intercellular communication between different types of cells. [39] [40] [41] Therefore, we performed additional experiments to explore the transfer of endothelial microvesicle-incorporated miR-92a-3p into vascular smooth muscle cells (VSMCs) and THP1 monocytes and monitored the subsequent phenotypic changes in recipient cells. However, we could not detect any uptake of miR-92a-3p-containing microvesicles into THP1 cells using fluorescence microscopy (Online Figure IXA) . Furthermore, qPCR revealed no changes in miR-92a-3p levels in monocytes after microvesicle-miR-92a-3p treatment (Online Figure IXB) . Subsequently, there was no influence of EMVs on THP1 activation and transmigration (Online Figure  XA and XB) . In contrast, fluorescence microscopy demonstrated that microvesicle-miR-92a-3p can be internalized by VSMCs (Online Figure XIA) . The transfer of miR-92a-3p into VSMCs via EMVs was further ensured by using copy number assays (Online Figure XIB) . Next, we aimed to explore the biological function of EMV-incorporated miR-92a-3p in target VSMCs. Treatment of target VSMCs with EMVs promoted VSMC migration and proliferation (Online Figure   XII) . Similarly, EMV-mediated effects on VSMCs were abolished using EMV miR-92a-downregulated . These findings indicate that EC-secreted miR-92a-3p can be internalized by and alter the function of not only ECs but also of VSMCs.
Because circulating EMVs containing functional miR92a-3p might exact their main biological effect on target ECs, we aimed to elucidate the potential underlying mechanisms of miR-92a-3p-induced angiogenic responses in target ECs.
EMV-Mediated Transfer of Functional miR-92a-3p Regulates Angiogenesis in Recipient ECs Through a THBS1-Dependent Mechanism
To explore the underlying mechanism of EMV-transferred miR-92a-3p in the regulation of angiogenic functions in recipient ECs, RT 2 Profiler PCR array analysis was performed to measure the differential expression of 84 key genes involved in modulating the biological processes of angiogenesis. Because miRs normally regulate cellular phenotype by downregulating target mRNAs, we focused on genes that were downregulated in recipient ECs after treatment with vehicle, EMVs, or EMV miR-92a-downregulated . The profiler PCR array results showed that 53 genes were downregulated in ECs by EMVs with functional miR-92a-3p compared with control cells and Figure 5 . Endothelial cell-derived microvesicle (EMV)-incorporated miR-92a-3p is transferred into recipient endothelial cells (ECs). A, Cyanine 3 dye (Cy3)-labeled miR-92a-3p was transfected into ECs, EMVs were purified from these cells, and then the EMVs were labeled with PKH67. PKH67-labeled EMVs that contained Cy3-labeled miR-92a-3p were cultured with recipient ECs for 6 h. The nuclei of the cells were stained with 4′,6-diamidino-2-phenylindole (DAPI), and pictures were taken by immunofluorescence microscope. Scale bar=10 μm. (Aa) Labeling nDNA using DAPI (blue). (Ab) EMV membranes were labeled with PKH67 (green). (Ac) MiR-92a-3p was labeled with Cy3 (red). (Ad) The Cy3-miR-92a-3p signals colocalized with PKH67 in the merged image. (Ae) As a negative control for detection of the Cy3 signals, ECs were cultured with nonlabeled miR-92a-3p within EMVs (merge image). (Af) As a negative control for PKH67, ECs were cultured with unlabeled EMVs containing nonlabeled miR-92a-3p (merge image). B, MiR-92a-3p expression in target ECs that were treated with EMVs or vehicle was quantified using copy number analysis (***P<0.001, n=4, by Student t test). February 15, 2019 40 genes were downregulated by functional EMV compared with EMV miR-92a-downregulated treatment (Online Figure XIII) . The 5 most downregulated genes in EMV versus control and EMV versus EMV miR-92a-downregulated were separately identified and further examined ( Figure 7A through 7C ). Among those, 3 genes were simultaneously downregulated in response to EMV treatment compared with control and EMV miR-92a-downregulated : THBS1 (thrombospondin 1), TEK (TEK receptor tyrosine kinase), and ANGPT1 (angiopoietin 1; Figure 7C ). Single realtime PCR experiments showed that only THBS1-a known target of miR-92a-3p 42 -was downregulated in target ECs by EMVs in an miR-92a-3p-dependent manner (Online Figure  XIV) . Furthermore, Western blot experiments and ELISAs confirmed an miR-92a-3p-dependent downregulation of THBS1 expression in target ECs and supernatants after EMV treatment (Figure 7D through 7F; Online Figure XV) . These findings are consistent with the initial array results showing no change of THBS1 expression in target ECs after treatment with EMV miR-92a-downregulated compared with the control cells (Online Figure XVI) . Given the known role of THBS1 as a negative regulator of EC migration and proliferation, 43 further experiments were performed to evaluate whether miR-92a-3p in EMVs can inhibit THBS1 expression in target ECs and thereby promote EC migration and proliferation. Therefore, ECs were transfected with small interfering RNA against THBS1 or a scrambled small interfering RNA as a control. Efficient THBS1 downregulation in target cells by using interfering RNA was confirmed by real-time PCR (Online Figure  XVII) . Downregulation of THBS1 significantly increased EC migration and proliferation, confirming that THBS1 is a negative regulator of EC migration and proliferation ( Figure 8A  through 8D ). , or vehicle. A and B, A scratch-migration assay was performed, and representative images of cells migrating into the scratched region after 6 h are shown. Quantitative analysis of migration was measured as a percentage of total cell-free area (*P<0.05, **P<0.01, ***P<0.001, n=6, by 1-way ANOVA with Bonferroni multiple comparisons test). Scale bar=20 μm. C and D, BrdU incorporation was determined by immunofluorescence (red). Nuclei were stained with DAPI (blue). The percentage of bromodeoxyuridine (BrdU)-positive cells was compared with the total number of cells (*P<0.05, **P<0.01, ***P<0.001, n=5, by 1-way ANOVA with Bonferroni multiple comparisons test). Scale bar=20 μm. Magnification ×100. E and F, Tube formation assays of ECs. Capillary tubes were photographed with an immunofluorescence microscope. Scale bar=100 μm. Tube nodes were measured and quantitatively analyzed using Image-Pro Plus (*P<0.05, n=6, by 1-way ANOVA with Bonferroni multiple comparisons test).
Discussion
miRs are currently being explored as biomarkers in a wide range of cardiovascular conditions, including atherosclerotic diseases. Circulating miRs are detectable and remarkably stable in bodily fluids, such as blood and urine. Microvesicles represent important transport vehicles for miRs by separating them from circulating RNases by a membrane. 44 Increasing evidence suggests that CAD patients show elevated levels of circulating microvesicles, which might be actively involved in the progression of vascular dysfunction in atherosclerotic conditions. 19 However, in our clinical study, circulating EMV numbers showed no significant differences when comparing patients without CAD, stable CAD, and ACS, most probably because of large SDs and a limited number of patients.
To date, the biological content of circulating microvesicles in patients with or without CAD is vastly unknown. Previously, we showed that microvesicle-incorporated, but not freely circulating expression levels of, miR-126 and miR199a predicted cardiovascular events in patients with stable CAD. 19 Therefore, we focused on analyzing the expression of microvesicle-incorporated miRs in this study. Analysis of circulating microvesicle-miRs showed significantly increased levels of miR-92a-3p in patients with stable CAD and ACS in comparison with patients without CAD, whereas miR-126 and miR-199a levels were not significantly different. These findings emphasize a potential role for miR-transporting microvesicles in the regulation of vascular health, which then is altered under atherosclerotic conditions. Analysis of circulating miRs in patients has 3 main challenges: first, circulating miR levels commonly show high variations that depend on patient characteristics, for example, age, sex, and medical history. Second, because there is no endogenous control, an exogenous control has to be added to normalize miR levels and compare between patient groups. Third, the methods used for collection, preparation, and storage of plasma samples may result in variability of miR levels, which could be caused by cell lysis or miR degradation. To overcome these inadequacies, several measures have been taken in our study. By using a relatively high number of patients (n=223), we reduced the possibility of coincidental discoveries. Furthermore, we used a homogenic patient collective (Online Table I ) with the aim to eliminate as much interindividual variability as possible, and plasma samples were frozen immediately after collection to reduce possible degradation of miRs. Cel-miR-39 was used as a spike-in control, which is, to our knowledge, the most widely used normalization approach for miR expression analysis in a clinical setting. 14, [45] [46] [47] [48] Moreover, the use of appropriate statistical methods minimizes the probability of potential false-positive or false-negative results. Finally, the selection of target miRs was done using real-time PCR arrays, and the selected 9 miRs have a relatively stable expression level in all the array samples. However, with the continued development of novel miR analysis methods, better methods with a lower fold-change of variability may be applied in clinical miR studies.
We further explored the cellular origins of microvesiclebound miR-92a-3p in CAD patients. It has been shown that miR-92a is highly expressed in various cell types, such as ECs, platelets, and monocyte-lineage cells. 38, 49, 50 The high expression of miR-92a-3p in sorted patient-derived CD31+/ CD42b− microvesicles on one hand and in EC-derived EMVs in vitro on the contrary, suggests that circulating microvesiclemiR-92a-3p is mainly of endothelial cell origin, which is in line with an increasing body of evidence to this effect. 51, 52 In analogy to our clinical findings, in vitro experiments demonstrated that miR-92a-3p was dose-dependently upregulated after oxLDL and IL-6 stimulation in ECs and EC-derived EMVs, representing 2 independent proatherogenic stimuli. In addition, oxLDL increased the amount of p-STAT3 (phosphorylated [active] STAT3), which then dimerizes and translocates into the nucleus to promote transcription of target genes. 53 Previous studies have shown that miR-92a expression was upregulated by p-STAT3 as transcription factor in ECs and lung cancer cells. 54, 55 A highly conserved STAT3-binding site in the promoter of the EFCAB12 gene was also identified, which encodes the entire miR-17-92 cluster. 56 In summary, we found that oxLDL activated STAT3 signaling and thus increased the expression of miR-92a-3p in parent ECs and EMVs, suggesting a novel mechanism of oxLDL regulation of miR-92a-3p expression in ECs and EMVs ( Figure 8E) .
Previous studies have shown that a loss of function of miR-92a resulted in smaller embryos and immediate postnatal death of all animals. This is likely because of severe , by 1-way ANOVA with Bonferroni multiple comparisons test). Scale bar=20 μm. C and D, Bromodeoxyuridine (BrdU) incorporation was determined by immunofluorescence (red). Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; blue). The number of BrdU-positive cells was compared with the total number of cells (****P<0.0001, n=10, by 1-way ANOVA with Bonferroni multiple comparisons test). Scale bar=20 μm. Magnification ×100. E, Proposed mechanism: OxLDL (oxidized low-density lipoprotein) increased microRNA (miR-92a-3p) expression in parent ECs and EMVs by activating STAT3. EMVs released from parent ECs contain and transfer miR-92a-3p into adjacent cells. MiR-92a-3p-mediated inhibition of THBS1 promotes the migration, proliferation, and angiogenesis of adjacent ECs. ventricular septal defects in the hearts of mice lacking miR92a. 57 Furthermore, miR-92a has been shown to be a crucial regulator of angiogenesis and vascular integrity. Daniel et al 58 showed that inhibition of miR-92a enhances re-endothelialization and prevents neointimal lesion formation after endovascular injury. In line with these findings, inhibition of miR-92a increased endothelial proliferation and migration in vitro and reduced neointimal formation after balloon injury or arterial stenting in vivo. 59 Consistent with these results, Hinkel et al 23 showed that efficient inhibition of miR-92a exhibits beneficial pleiotropic effects that may contribute to the improved recovery of heart function after ischemia/reperfusion injury in a preclinical pig model. Taken together, these results demonstrate that miR-92a plays an important role in developmental and pathological angiogenesis. Whereas inhibition of miR-92a seems to mediate vascular regeneration and reduce vascular remodeling, the functional role of miR-92a-3p in EMVs is unclear. To explore whether EMV-incorporated miR-92a-3p might play a functional role in the regulation of vascular performance, we first examined whether EMV-bound miR-92a-3p was taken up by the target ECs. By using Cy3-labeled miR-92a-3p and PKH67-labeled EMVs, we found that miR-92a-3p was transferred via EMVs into recipient ECs. Next, loss-of-function experiments showed that EMVs promoted EC migration, proliferation, and tube formation in a miR-92a-3p-dependent manner in vitro; this effect was abrogated by the downregulation of miR-92a-3p in EMVs. Consistent with our results, Umezu et al 60 have shown that exogenous miR-92a addition using exosomes enhanced EC migration and tube formation. Conversely, Bonauer et al 61 demonstrated that overexpression of miR-92a in ECs repressed angiogenesis, both in vitro and in vivo. Based on our findings and the evidence presented above, intracellular levels of miR-92a in ECs can be in elevated in 2 ways: (1) direct upregulation using transfection of a precursor miR-92a; (2) delivery of exogenous miR-92a via biological transporting cargoes, for example, exosomes or microvesicles. However, although the 2 ways both result in higher cellular levels of miR-92a, the resulting cellular function and phenotype may differ. In summary, the role of miR-92a in the regulation of angiogenesis is still controversial and may vary depending on the experimental model used and method of regulating miR-92a levels.
MiR-92a regulates angiogenesis and has multiple mRNA targets. Bonauer et al 61 demonstrated that miR-92a could directly target ITGA5 (integrin α5). Likewise, Zhang et al 38 demonstrated that phosphatase and tensin homolog is a direct target of miR-92a and phosphatase and tensin homolog is known to play a central role in regulating angiogenesis. Our PCR-based gene expression array results suggested that THBS1, TEK, and ANGPT1 were downregulated by EMVbound miR-92a-3p in target ECs. However, single real-time PCR experiments revealed that only THBS1 was inhibited by EMV-contained miR-92a-3p. THBS1 was one of the first endogenous inhibitors of angiogenesis to be identified.
62 THBS1 inhibits angiogenesis directly by interacting with specific receptors and stimulating Fas/Fas ligand-mediated apoptosis of ECs, or it acts indirectly by modulating the activity of several angiogenic factors. 42 Interestingly, tumor angiogenesis is also associated with a significant upregulation of cellular levels of miR-92a, leading to downregulated THBS1, and the therapeutic efficacy of a THBS1 inhibitor has already been evaluated in a phase 2 clinical trial. 42, 63, 64 Finally, our functional in vitro experiments confirmed that THBS1 negatively regulates EC migration and proliferation, which are cellular processes that mediate angiogenesis.
Besides ECs, VSMCs are also key players, participating in the regulation of angiogenesis and vascular remodelling. 65 ECs, which are located in the innermost layer of the blood vessel and are in contact with the circulating blood, exert a constant influence on the underlying VSMCs. There is increasing evidence that microvesicles are the critical mediators in the cellular cross talk between the 2 different cell types. 66, 67 In this study, we demonstrated that EMVs can be internalized and can modulate the functional properties of target ECs and VSMCs by transferring miR-92a-3p, improving the understanding of intercellular communication in the vascular wall.
In summary, our findings offer new mechanistic insights into the regulation of angiogenesis: (1) 2 independent atherosclerotic stimuli (oxLDL and IL-6) increase miR-92a-3p expression in donor ECs and EMVs; (2) exogenous miR-92a-3p, transferred by EMVs, promotes an angiogenic phenotype in target ECs; and (3) mechanistically, EMV-miR-92a-3p downregulates mRNA of the antiangiogenic protein THBS1 in target ECs, promoting angiogenesis ( Figure 8E ). Based on our findings, one can speculate that proatherogenic stimuli promote the release of miR-92a-3p-containing EMVs as messengers carrying a potentially regenerative signal that can be taken up by target cells further downstream in the blood to promote angiogenesis under conditions of vascular damage. These results suggest new aspects to the role and function of miR-92a-3p in EMVs, as a potential regenerative messenger in intercellular communication. However, some limitations of our study need to be mentioned. First, although miR-92a-3p shows differential expression between patients with or without CAD, the level of difference is modest. Therefore, microvesicle-incorporated miR-92a-3p has limited clinical power as diagnostic biomarker. However, the main purpose of this translational study was to identify differentially expressed miRs among no CAD, stable CAD, and ACS patients and further to study the function and mechanism of target miRs in the regulation of vascular integrity. Additionally, we generated EMV miR-92a-downregulated through efficient miR-92a-3p downregulation in EMV parent cells by using miR-92a-3p inhibitor. Although expression of the other 8 analyzed miRs was neither affected in EMV donor cells nor in EMVs as confirmed by real-time PCR, it is technically difficult to totally exclude changes of any other biological contents in EMVs after miR regulation. Furthermore, some important questions remain and will be addressed in future studies. First, the analysis of circulating miRs bound to cargos other than microvesicles (eg, HDL or Ago proteins) would be of interest for future studies. Second, only a selected number of miRs, based on our own array results and previously published data, have been analyzed. Finally, although we see a specific effect of miR-92a-3p in EMVs, we cannot rule out the influence of other miRs or bioactive molecules present in EMVs on our results.
